Systemic Therapy for Metastatic Pancreatic Cancer

Area of Science:

• Oncology
• Medical Genetics
• Pharmacology

Background:

• Pancreatic cancer, particularly metastatic pancreatic ductal adenocarcinoma (mPDAC), presents a significant clinical challenge with poor prognosis.
• Chemotherapy has improved survival and quality of life compared to supportive care alone.
• Recent advances include sequential treatment strategies for mPDAC.

Purpose of the Study:

• To review current and emerging treatment options for metastatic pancreatic cancer.
• To highlight the importance of genetic profiling, specifically BRCA1/2 mutations, for personalized therapy.
• To discuss the efficacy of different chemotherapeutic regimens and novel therapeutic approaches.

Main Methods:

• Review of current clinical guidelines and recent research findings in mPDAC treatment.
• Analysis of first-line and second-line treatment options based on patient performance status.
• Evaluation of targeted therapies, including PARP inhibitors and immune checkpoint inhibitors.

Main Results:

• First-line options include FOLFIRINOX or gemcitabine plus nab-paclitaxel for good performance status; gemcitabine monotherapy for poorer status.
• Olaparib improves progression-free survival in BRCA1/2-mutated mPDAC patients post-platinum chemotherapy.
• Second-line treatment with 5-FU/FA plus nanoliposomal irinotecan shows improved overall survival over 5-FU/FA alone.

Conclusions:

• Early BRCA1/2 mutation testing in mPDAC is recommended due to potential benefits from platinum-based chemotherapy and PARP inhibitors.
• Sequential treatment strategies, including novel combinations and targeted therapies, are crucial for improving mPDAC outcomes.
• Further research into identifying novel subgroups and utilizing organoid-informed decisions may enhance therapeutic efficacy.